Abiraterone

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abiraterone and local guidelines before prescribing.

CYP17 inhibitor (antiandrogen therapy)

Mechanism

Irreversible inhibitor of CYP17, blocking androgen synthesis in testes, adrenals and tumour.

Uses

Metastatic castration-resistant or high-risk hormone-sensitive prostate cancer, with prednisolone.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Hypertension, hypokalaemia, fluid retention, liver enzyme rise, fatigue.

Interactions

CYP2D6 substrates (e.g. metoprolol) levels rise; strong CYP3A4 inducers lower levels.

Contraindications and cautions

Severe liver impairment; caution in heart failure, hypertension, hypokalaemia

Monitoring

BP, potassium, LFT, fluid status

Pregnancy and breastfeeding

Not for use in women; contraception needed by male partners

Renal and hepatic impairment

Reduce in moderate liver impairment; avoid in severe

Overdose and reversal

Supportive care

Special advice

Always given with a corticosteroid to limit mineralocorticoid excess; monitor BP, potassium, fluid status and LFTs.

More from the textbook: uses, cautions and other points
Where it is discussed in the book